L-Arginine-eNOS-NO Functional System in Brain Damage and Cognitive Impairments in Cerebral Small Vessel Disease
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241914537 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Larisa A Dobrynina und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Neurology, 80 Volokolamskoe Shosse, 125367 Moscow, Russia. Hauptthemen laut MEDLINE: Brain Injuries, Cerebral Small Vessel Diseases, Cognitive Dysfunction, White Matter. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Cerebral small vessel disease (CSVD) is a significant cause of cognitive impairment (CI), disability, and mortality. The insufficient effectiveness of antihypertensive therapy in curbing the disease justifies the search for potential targets for modifying therapy and indicators supporting its use. Using a laser-assisted optical rotational cell analyzer (LORRCA, Mechatronics, The Netherlands), the rheological properties and deformability of erythrocytes before and after incubation with 10 μmol/L of L-arginine, the nitric oxide (NO) donor, blood–brain barrier (BBB) permeability assessed by dynamic contrast-enhanced MRI, clinical, and MRI signs were studied in 73 patients with CSVD (48 women, mean age 60.1 ± 6.5 years). The control group consisted of 19 volunteers (14 women (73.7%), mean age 56.9 ± 6.4 years). The erythrocyte disaggregation rate (y-dis) after incubation with L-arginine showed better performance than other rheological characteristics in differentiating patients with reduced NO bioavailability/NO deficiency by its threshold values. Patients with y-dis > 113 s−1 had more severe CI, arterial hypertension, white matter lesions, and increased BBB permeability in grey matter and normal-appearing white matter (NAWM). A test to assess changes in the erythrocyte disaggregation rate after incubation with L-arginine can be used to identify patients with impaired NO bioavailability. L-arginine may be part of a therapeutic strategy for CSVD with CI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center of Neurology, 80 Volokolamskoe Shosse, 125367 Moscow, Russia.
ORCID-Profile: Larisa A Dobrynina, Elena I Kremneva, Maryam R Zabitova, Elena V Gnedovskaya
Förderung
- Russian Science Foundation
Zitieren
APA
Dobrynina, L. A., Shabalina, A. A., Shamtieva, K. V., Kremneva, E. I., Zabitova, M. R., Krotenkova, M. V., Burmak, A. G., & Gnedovskaya, E. V. (2023). L-Arginine-eNOS-NO Functional System in Brain Damage and Cognitive Impairments in Cerebral Small Vessel Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914537
Vancouver
Dobrynina LA, Shabalina AA, Shamtieva KV, Kremneva EI, Zabitova MR, Krotenkova MV, et al. L-Arginine-eNOS-NO Functional System in Brain Damage and Cognitive Impairments in Cerebral Small Vessel Disease. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914537
BibTeX
@article{Dobrynina2023,
author = {Dobrynina, Larisa A and Shabalina, Alla A and Shamtieva, Kamila V and Kremneva, Elena I and Zabitova, Maryam R and Krotenkova, Marina V and Burmak, Anastasiia G and Gnedovskaya, Elena V},
title = {L-Arginine-eNOS-NO Functional System in Brain Damage and Cognitive Impairments in Cerebral Small Vessel Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241914537}
}
EUVIMED